U.S. Food and Drug Administration approves Gilead’s Sovaldi™ (sofosbuvir) for the treatment of chronic hepatitis C - MARG
858.277.5678
Quality Patient Care. Exceptional Research.
News

U.S. Food and Drug Administration approves Gilead’s Sovaldi™ (sofosbuvir) for the treatment of chronic hepatitis C

Download the PDF